High Efficacy of Sofosbuvir/Velpatasvir plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-Infected Patients, Including those Previously Treated with Direct-acting Antivirals
- Author
- eViralHepatitis Review
- Published
- Thu 26 May 2016
- Episode Link
- https://shows.acast.com/eviralhepatitisreview/episodes/5fa6e85d4a2a5c52d1e331ce
Volume 4, Issue 8, Part 1.
Raymond T. Chung, MD from Harvard Medical School interviews Dr. Eric Lawitz from the University of Texas Health Science Center about his presentation: High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals presented at the April 2016 EASL meeting.
The post High Efficacy of Sofosbuvir/Velpatasvir plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-Infected Patients, Including those Previously Treated with Direct-acting Antivirals appeared first on DKBmed Radio.
Hosted on Acast. See acast.com/privacy for more information.
